Cadenza Bio, Inc.
cadenza.bio
Actively hiring
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
5
US Form 5500 (plan participants) · Dec 2025 · 0% in a year
Backers
2
Cortado Ventures, Illinois Ventures
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Debt Financing | Dec 2023 | $2.4M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Cadenza Bio, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Elaine HammExecutive Officer, DirectorSEC Form D
Carol CurtisExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Cortado Ventures 
Illinois Ventures Similar startupsby what they do, their industry and backers
Light Horse is a small molecule drug discovery company that is leading the way in a.
The only integrated full-stack AI platform for small molecule drug discovery.
Iktos combines generative AI, retrosynthesis and robotics to accelerate small-molecule drug discovery from design to preclinical candidate…
Lipum is a biopharmaceutical company specialized on a novel way to treat chronic inflammatory diseases.
A biotech company developing better medicines for patients with autoimmune and inflammatory diseases. Leveraging powerful insights into the…
STORM Therapeutics is a pioneer in the field of RNA epigenetics. We are an emerging biotechnology company in Cambridge, UK, focused on…
News
Cadenza Bio Announces Peer-Reviewed Study Showing Oral, Brain-Penetrant ERβ Ligands Drive Remyelination and Functional Recovery in MS Models
Cadenza Bio, Inc. today announced that a collaborative study, "Chloroindazole based Estrogen Receptor β ligands with favorable pharmacokinetics promote functional remyelination and visual recovery," has been published in Scientific Reports (https://www.na
Read more
Report
Cadenza Bio, Inc. Announces Members of the Women
Cadenza Bio, Inc., a preclinical biotechnology company dedicated to developing small-molecule therapies for demyelinating and inflammatory disease, proudly announces the formation of its Women
Read more
Report
Cadenza Bio, Inc. Secures $2.44M in Oversubscribed Series Seed Financing
/PRNewswire/ -- Cadenza Bio, Inc. (Cadenza), a privately-held biotechnology company focused on developing novel small molecule compounds for demyelinating and...
Read more
Report
People
Elaine Hamm
Executive Officer, Director
Carol Curtis
Executive Officer, Director
Tom Denison
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Yukon
United States
HQ
10-50 est. staff
Financials
Total raised
$2.4M
Latest round
Debt Financing
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Debt Financing | 2023 | $2.4M | Details |